Gilead Sciences, Inc. (GILD): Price and Financial Metrics


Gilead Sciences, Inc. (GILD)

Today's Latest Price: $72.73 USD

3.03 (4.35%)

Updated Feb 24 3:52pm

Add GILD to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 338 in Biotech

See all "A" rated Strong Buy stocks

GILD Stock Summary

  • Gilead Sciences Inc's market capitalization of $81,095,833,729 is ahead of 97.59% of US-listed equities.
  • Of note is the ratio of Gilead Sciences Inc's sales and general administrative expense to its total operating expenses; just 16.8% of US stocks have a lower such ratio.
  • The volatility of Gilead Sciences Inc's share price is greater than that of only 1.83% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to GILD, based on their financial statements, market capitalization, and price volatility, are AMAT, VRTX, MU, QCOM, and LRCX.
  • GILD's SEC filings can be seen here. And to visit Gilead Sciences Inc's official web site, go to www.gilead.com.
GILD Daily Price Range
GILD 52-Week Price Range

GILD Stock Price Chart More Charts


GILD Price/Volume Stats

Current price $72.73 52-week high $74.52
Prev. close $69.70 52-week low $60.89
Day low $71.59 Volume 37,242,981
Day high $74.52 Avg. volume 13,162,900
50-day MA $65.90 Dividend yield 3.62%
200-day MA $65.49 Market Cap 92.01B

Gilead Sciences, Inc. (GILD) Company Bio


Gilead Sciences is a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs. The Company's primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.

GILD Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$72.73$110.03 58%

We started the process of determining a valid price forecast for Gilead Sciences Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Gilead Sciences Inc ranked in the 66st percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. The most interesting components of our discounted cash flow analysis for Gilead Sciences Inc ended up being:

  • Gilead Sciences Inc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than only 22.21% of tickers in our DCF set.
  • As a business, Gilead Sciences Inc experienced a tax rate of about 23% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 90.51% of stocks generating free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%55%
1%56%
2%58%
3%59%
4%61%
5%63%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as GILD, try PDEX, SEM, RSCF, REGN, and HCA.


GILD Latest News Stream


Event/Time News Detail
Loading, please wait...

GILD Latest Social Stream


Loading social stream, please wait...

View Full GILD Social Stream

GILD Price Returns

1-mo 15.17%
3-mo 9.11%
6-mo 16.43%
1-year 14.89%
3-year 14.66%
5-year -20.49%
YTD 11.93%
2019 7.88%
2018 -9.92%
2017 2.96%
2016 -27.59%
2015 8.63%

GILD Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full GILD Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6448 seconds.